Ratification of EU-US Trade Deal Could Be Imminent Amid White House’s Latest Tariff Adjustments

Why It Matters

The tariff shift removes the biggest political hurdle, unlocking $1.35 trillion of cross‑border commitments and reshaping transatlantic supply chains.

Key Takeaways

• EU‑US trade pact nearing ratification after tariff revisions
• Pharma duties capped at 15% for EU, Japan, Korea
• U.S. steel and aluminum tariffs reduced to 15% baseline
• EU commits $750B energy purchase, $600B investment

Pulse Analysis

The EU‑U.S. trade pact has lingered since its July 2025 handshake at Turnberry, hampered by President Trump’s aggressive tariff agenda and a February Supreme Court decision that struck down large portions of the International Emergency Economic Powers Act (IEEPA) tariffs. European legislators paused ratification, fearing that unpredictable duties would erode the economic benefits of the agreement. Meanwhile, competing trade talks with India and the United Kingdom added pressure on Washington to demonstrate a consistent, rules‑based approach. The latest policy shift therefore arrives at a critical juncture for transatlantic commerce.

On Thursday, the White House announced that name‑brand pharmaceuticals will face a maximum 100% duty, but the EU, Japan, South Korea and Switzerland will benefit from a reduced 15% rate, with the United Kingdom receiving a 10% tariff. Steel and aluminum duties were also restructured, eliminating the previous 50% surcharge and setting a uniform 15% baseline, while certain niche categories retain a 25% special rate. These adjustments directly address the concerns raised by European trade officials, removing the most contentious tariff barrier and paving the way for the Senate and European Parliament to move forward with ratification.

The revised tariff framework unlocks roughly $1.35 trillion of bilateral commitments, including $750 billion in U.S. energy purchases and $600 billion of European investment, while offering U.S. manufacturers duty‑free access to the 27‑member bloc. Analysts expect the deal to boost transatlantic supply‑chain resilience, especially in high‑tech and pharmaceutical sectors, and to temper inflationary pressure from imported inputs. With the tariff hurdle cleared, attention now turns to implementation details, such as rules of origin and enforcement mechanisms, which will determine how quickly the promised economic gains materialize.